Pipeline
Programs Discovery Preclinical Phase 1 Phase 2 Phase 3 Collaborator Rights
Infectious Disease Programs
HBV BRII-835 (VIR-2218)
China
BRII-179 (VBI-2601)
China
MDR TB
Mycobacteria
BRII-658
China
MDR Gram
[-] infections
BRII-636 (QPX-7728)
China
BRII-672 (QPX-7831)
China
BRII-693 (QPX-9003)
China
HIV BRII-732
  Global
BRII-778
  Global
SARS-CoV-2 BRII-196
Global
BRII-198
Global
Undisclosed Undisclosed
China
Various
China
Central Nervous System Disease Programs
Undisclosed BRII-296
  Global
Undisclosed
  Global
Option for an exclusive license for Greater China territory.
up
×
×
HBV
BRII-835
siRNA
Stage: Phase 2 
A novel, investigational RNA interference (RNAi) therapeutic designed to inhibit expression of all HBV proteins, including hepatitis B surface antigen (HBsAg). Viral protein knockdown may help restore the patient’s own immune response to HBV, thereby offering people living with chronic HBV the potential for a functional cure.
×
HBV
BRII-179
Recombinant, Protein-based Immuno-therapeutics
Stage Phase 2
Uniquely formulated to target both B-cell and T-cell immunity through multiple mechanisms of action, including neutralization of the circulating hepatitis B virus, blocking hepatitis B infection of hepatocytes mediated through Pre-S1, and enabling immune-mediated clearance of HBV-infected hepatocytes.  Where many investigational agents work inside the infected liver cells downstream of transcription, BRII-179 is designed to impact the key extracellular steps in the HBV lifecycle in order to sustain immunologic control over the infection.
×
MDR TB Mycobacteria
BRII-658
Stage: Phase 1
Antibacterial compound with a completely novel mechanism of action targeting multi-drug resistant tuberculosis.
×
MDR Gram Negative Bacteria
BRII-636
Beta-lactamase inhibitor
Stage: Preclinical
An intravenously administered, beta-lactamase inhibitor (BLI) combination targeting all WHO-designated critical pathogens of extensively drug resistant Acinetobacter, Enterobacteriaceae, and Pseudomonas in hospitalized patients.
×
MDR Gram Negative Bacteria
BRII-672
Beta-lactamase inhibitor
Stage: Preclinical
An orally administered BLI combination for the treatment of multi-drug resistant Gram-negative bacterial infections targeting extended spectrum beta-lactamase (ESBL) and/or carbapenemase producing Enterobacteriaceae as well as an oral step-down therapy to BRII-636
×
MDR Gram Negative Bacteria
BRII-693
Next-generation Polymyxin
Stage: Preclinical
An IV-administered, targeted spectrum synthetic polymyxin with an enhanced therapeutic profile designed to address extensively drug resistant infections caused by Pseudomonas and Acinetobacter
×
Novel treatment of HIV infections
Brii Bio has a very strong and proven track-record of delivering novel therapies to patients around the globe who are living with HIV. Current standard of care treatments has not addressed substantial patients’ need.
×
BRII-732
Stage: Preclinical
Led by our very experienced small and large molecule discovery leaders, we are moving this program toward clinical investigation.
×
BRII-778
Stage: Preclinical
Led by our very experienced small and large molecule discovery leaders, we are moving this program toward clinical investigation.
×
SARS-CoV-2
BRII-196
Human Monoclonal Antibody
Stage: Preclinical
Isolated from a patient who has recovered from COVID-19, BRII-196 can completely block viral entry and neutralize live SARS-CoV-2 infection in cell culture assays. It binds to a highly conserved epitope on the Spike protein and has the potential of becoming an effective therapy against the COVID-19 pandemic.
×
SARS-CoV-2
BRII-198
Human Monoclonal Antibody
Stage: Preclinical
Isolated from a patient who has recovered from COVID-19, it potently neutralizes live SARS-CoV-2 infection. BRII-198 binds to a different epitope on the Spike protein and has additive to synergistic effect when combined with BRII-196. It has the potential of becoming an effective therapy against the COVID-19 pandemic.
×
Neurologic and Psychiatric Programs
We are advancing a preclinical pipeline focused on CNS diseases where we see vast opportunities to improve patient care by accelerating the development and delivery of breakthrough medicines and to open doors for our partners. We currently have multiple compounds in preclinical development.
×
BRII-296
Stage: Preclinical
We are advancing a preclinical pipeline focused on CNS diseases where we see vast opportunities to improve patient care by accelerating the development and delivery of breakthrough medicines and to open doors for our partners.
×
Undisclosed
Stage: Discovery
We are advancing a preclinical pipeline focused on CNS diseases where we see vast opportunities to improve patient care by accelerating the development and delivery of breakthrough medicines and to open doors for our partners.